Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Dec 28;27(6):545-6.

[Clinical observation of granisetron in preventing postoperative nausea and vomiting following supratentorial craniotomy]

[Article in Chinese]
Yun-jiao Wang  1 , Zhi-gang Cheng, Qu-lain Guo
Affiliations
  • PMID: 12658936
Clinical Trial

[Clinical observation of granisetron in preventing postoperative nausea and vomiting following supratentorial craniotomy]

[Article in Chinese]
Yun-jiao Wang et al. Hunan Yi Ke Da Xue Xue Bao. .

Abstract

Objective: To observe the prophylactic effect of granisetron on postoperative nausea and vomiting (PONV) after supratentorial craniotomy.

Methods: Seventy ASA I-II patients undergoing elective supratentorial craniotomy were randomly and double-bindly divided into two groups: control group (Group C, n = 35) and granisetron group (Group G, n = 35). All the patients received either 0.9% NS (Group C) or granisetron 3 mg (Group G) via intravenous injection. The incidences of postoperative nausea and vomiting were recorded at 24 h, 48 h, 72 h after supratentorial craniotomy.

Results: The incidence of PONV in Group G was lower than that in Group C (25.7% vs 57.1%, P < 0.01). The incidence of server nausea with vomiting or vomiting in Group G was lower than that in Group C (17.2% vs 48.6%, P < 0.01).

Conclusion: Granisetron can be used effectively and safely to prevent PONV in supratentorial craniotomy.

PubMed Disclaimer

LinkOut - more resources